One previous investigation of serum pre-RA samples (n = 79) failed to detect differences in RANKL serum levels as compared to controls [37] despite more recent reports showing signs of bone destruction in ACPA-positive individuals already before disease onset [38]. This evidence concerns the gene PRTN3 and rheumatoid arthritis.